MBX Biosciences

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on the bottom line, with a GAAP net loss of $37.1M compared to the anticipated $29.8M. GAAP EPS of -$0.78 was below the consensus mean of -$0.62. The variance was primarily driven by accelerated R&D spend ($31.0M) as the company initiates Phase 3 trials for canvuparatide. However, a strong cash position of $418.6M provides a runway into 2029, and clinical progress in the obesity pipeline remains a key catalyst.